Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AMY-101 in Healthy Volunteers
NCT03316521Phase 1Completed
- Sponsor
- Amyndas Pharmaceuticals
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of AMY-101 in complement-mediated diseases (CMDs) (2 arms), sponsored by Amyndas Pharmaceuticals. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. Started Apr 2017; status: completed.
02
Drugs
AMY-101
03
Conditions
complement-mediated diseases (CMDs)
Beyond the preview
Go deeper on NCT03316521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316521.